

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket No: SALK1520-2

MADD ent application of

EVANS, RONALD M. et al.

RECEIVED

Serial No. 09/042,488

AUG 3 1 2001

Filed: March 16, 1998

TECH CENTER 1600/2900

For: METHODS FOR MODULATING EXPRESSION OF EXOGENOUS GENES IN MAMMALIAN

SYSTEMS, AND PRODUCTS REALTED THERETO

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

Assistant Commissioner for Patents Washington, D.C. 20231
Box SEQUENCE

Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

- the submission, filed herewith in accordance with 37
 C.F.R. § 1.821(g), does not include new matter;
- 2. the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same; and
- 3. all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United

Serial No. 09/042,488

States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted,

Coburn

HARBOR CONSULTING

Intellectual Property Services 1500A Lafayette Road Suite 262 Portsmouth, N.H. 800-318-3021

PE	Application No.	Applicant RECEIVED
Notice to Comply	09042488	EVANS et al
	Examiner	Art Unit AUG 3 1 2001
\ & /	KAUSHAL	1633 TECH CENTER 1600/20
NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIBE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES		
Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).		
The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):		
1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).		
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).		
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).		
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."		
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).		
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).		
7. Other:		
Applicant Must Provide: ☑ An initial or substitute computer readable form (CRF) or	copy of the "Sequence Listing".	· · · · · · · · · · · · · · · · · · ·
☑ An initial or substitute paper copy of the "Sequence Lisspecification.	sting", as well as an amendment d	lirecting its entry into the
A statement that the content of the paper and comput no new matter, as required by 37 C.F.R. 1.821(e) or 1.821.	er readable copies are the same (f) or 1.821(g) or 1.825(b) or 1.82	e and, where applicable, include 5(d).
For questions regarding compliance to these requ	uirements, please contact:	
For Rules Interpretation, call (703) 308-4216		
For CRF Submission Help, call (703) 308-4212		
PatentIn Software Program Support Technical Assistance	702 207 0200	•
	/ U3-20/-U2UU	•

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

To Purchase Patentin Software.....703-306-2600